Michael Gilman

Michael Gilman was the founder of Stromedix, Inc. (2006), where the title held was Chief Executive Officer in 2012.
Dr. Gilman was the founder of X4 Pharmaceuticals, Inc. (2014), holding the title of Director.
Dr. Gilman is the founder of Padlock Therapeutics, Inc. (2014), serving as President, Director & Secretary.
Dr. Gilman was the founder of Obsidian Therapeutics, Inc. (2015), where the title held was Chief Executive Officer & Director from 2015 to 2019.
Dr. Gilman is currently Chief Executive Officer & Director at Arrakis Therapeutics, Inc. since 2019.
Dr. Gilman is a Director at Scholar Rock, Inc. since 2013.
Dr. Gilman is an Independent Director at Scholar Rock Holding Corp.
since 2013.
Dr. Gilman is a Scientific Advisor at FutuRx Ltd. Dr. Gilman was Director at EPIX Pharmaceuticals, Inc. Dr. Gilman was Director at Via Science, Inc. Dr. Gilman was Chief Scientific Officer & Executive VP at ARIAD Pharmaceuticals, Inc. from 1994 to 1999.
Dr. Gilman was Senior Vice President-Early-Stage Pipeline at Biogen, Inc. from 2012 to 2013.
Dr. Gilman was Executive Vice President-Research at Biogen, Inc. from 1999 to 2005.
Dr. Gilman completed undergraduate education at Massachusetts Institute of Technology in 1976.
Dr. Gilman earned a doctorate from the University of California, Berkeley in 1983.